Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) CEO Joel Lewis sold 27,731 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $3.91, for a total value of $108,428.21. Following the completion of the transaction, the chief executive officer directly owned 870,290 shares of the company’s stock, valued at approximately $3,402,833.90. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Joel Lewis also recently made the following trade(s):

• On Tuesday, January 6th, Joel Lewis sold 37,698 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.58, for a total value of $134,958.84.
• On Friday, January 2nd, Joel Lewis sold 18,571 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $77,998.20.
• On Wednesday, December 17th, Joel Lewis sold 7,829 shares of Galectin Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $55,272.74.
• On Wednesday, November 5th, Joel Lewis sold 200 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.00, for a total transaction of $1,200.00.
• On Tuesday, November 4th, Joel Lewis sold 14,420 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.07, for a total transaction of $87,529.40.
• On Monday, November 3rd, Joel Lewis sold 1,300 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.01, for a total transaction of $7,813.00.

Galectin Therapeutics Stock Down 11.1%

Shares of Galectin Therapeutics stock traded down $0.43 during trading on Tuesday, reaching $3.45. The company’s stock had a trading volume of 905,529 shares, compared to its average volume of 684,117. The company has a 50-day simple moving average of $5.34 and a two-hundred day simple moving average of $4.39. Galectin Therapeutics Inc. has a 1-year low of $1.07 and a 1-year high of $7.13. The company has a market cap of $222.42 million, a price-to-earnings ratio of -5.85 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, analysts anticipate that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year.

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Galectin Therapeutics by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock valued at $9,520,000 after purchasing an additional 63,419 shares during the period. Osaic Holdings Inc. grew its stake in Galectin Therapeutics by 3.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company’s stock valued at $2,670,000 after acquiring an additional 41,968 shares during the period. Jane Street Group LLC purchased a new stake in Galectin Therapeutics in the 2nd quarter worth $1,580,000. Wealthspire Advisors LLC raised its position in Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company’s stock worth $1,012,000 after acquiring an additional 81,144 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Galectin Therapeutics by 8.8% during the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company’s stock valued at $516,000 after purchasing an additional 34,300 shares in the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on GALT. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. HC Wainwright raised their price objective on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $11.00.

Key Stores Impacting Galectin Therapeutics

Here are the key news stories impacting Galectin Therapeutics this week:

• Negative Sentiment: CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. CEO Joel Lewis Form 4
• Negative Sentiment: CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. CFO Jack W. Callicutt Form 4
• Negative Sentiment: Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. Khurram Jamil Form 4
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short‑term selling pressure. Pomerantz Investor Alert

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.